UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Interleukin 2 in cancer therapy

Current medicinal chemistry, 2010, Vol.17 (29), p.3297-3302

2010

Volltextzugriff (PDF)

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours

British journal of cancer, 2014-01, Vol.110 (2), p.304-312

2014

Volltextzugriff (PDF)

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity

British journal of cancer, 2009-10, Vol.101 (7), p.1114-1123

2009

Volltextzugriff (PDF)

Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy

British journal of cancer, 2007-08, Vol.97 (4), p.513-522

2007

Volltextzugriff (PDF)

Computational methods in developing quantitative structure-activity relationships (QSAR): a review

Combinatorial chemistry & high throughput screening, 2006-03, Vol.9 (3), p.213-228

2006

Volltextzugriff (PDF)

Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates : requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins

Blood, 2000, Vol.95 (1), p.147-155

2000

Volltextzugriff (PDF)

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor

British journal of cancer, 2009-05, Vol.100 (9), p.1379-1384

2009

Volltextzugriff (PDF)

Circulating Angiogenic Cytokines in Patients with Advanced Non-Small Cell Lung Cancer: Correlation with Treatment Response and Survival

Cancer investigation, 2005, Vol.23 (3), p.193-200

2005

Volltextzugriff (PDF)

Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors

Cancer gene therapy, 2010-12, Vol.17 (12), p.855-863

2010

Volltextzugriff (PDF)

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

European journal of cancer (1990), 2022-10, Vol.174, p.S125-S126

2022

Volltextzugriff (PDF)

Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation

Clinical Immunology, 2005-11, Vol.117 (2), p.144-151

2005

Volltextzugriff (PDF)

Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials

Melanoma research, 2011-06, Vol.21 (3), p.165-174

2011

Volltextzugriff (PDF)

Single-institution Outcome of High-dose Interleukin-2 (HD IL-2) Therapy for Metastatic Melanoma and Analysis of Favorable Response in Brain Metastases

Anticancer research, 2009-10, Vol.29 (10), p.4189-4193

2009

Volltextzugriff (PDF)

1186PDSafety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

LARGE MULTTVALENT IMMUNOGEN VACCINE IN PATIENTS WITH METASTATIC MELANOMA

Anticancer research, 2008-10, Vol.28 (5C)

Dudek, A Z

2008

Volltextzugriff (PDF)

BLOOD OUTGROWTH ENDOTHELIAL CELL-BASED DELIVERY OF CANCER GENE THERAPY

Anticancer research, 2008-10, Vol.28 (5C)

Dudek, A Z

2008

Volltextzugriff (PDF)

Polymorphisms in DNA Repair Gene XRCC1 and Skin Cancer Risk: A Meta-analysis

Anticancer research, 2011-11, Vol.31 (11), p.3945-3952

2011

Volltextzugriff (PDF)

Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e20007-e20007

2009

Volltextzugriff (PDF)

Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C

The Journal of biological chemistry, 1997-12, Vol.272 (50), p.31785

1997

Volltextzugriff (PDF)

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5106-5106

2007

Volltextzugriff (PDF)

Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone

European journal of cancer (1990), 2008-11, Vol.44 (16), p.2506-2517

2008

Volltextzugriff (PDF)

A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates

American journal of clinical oncology, 2012-08, Vol.35 (4), p.386-392

2012

Volltextzugriff (PDF)

Molecular targets in the inhibition of angiogenesis

Expert opinion on therapeutic targets, 2003-08, Vol.7 (4), p.527-541

2003

Volltextzugriff (PDF)

Carbonic Anhydrase IX Expression Is Associated with Improved Outcome of High-dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma

Anticancer research, 2010-03, Vol.30 (3), p.987-992

2010

Volltextzugriff (PDF)

Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.1519-1519

2009

Volltextzugriff (PDF)

1 – 25 von 553

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(475)
Mit Volltextzugriff
(459)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Interleukin 2 in cancer therapy

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity

Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy

Computational methods in developing quantitative structure-activity relationships (QSAR): a review

Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates : requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor

Circulating Angiogenic Cytokines in Patients with Advanced Non-Small Cell Lung Cancer: Correlation with Treatment Response and Survival

Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation

Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials

Single-institution Outcome of High-dose Interleukin-2 (HD IL-2) Therapy for Metastatic Melanoma and Analysis of Favorable Response in Brain Metastases

1186PDSafety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment

LARGE MULTTVALENT IMMUNOGEN VACCINE IN PATIENTS WITH METASTATIC MELANOMA

BLOOD OUTGROWTH ENDOTHELIAL CELL-BASED DELIVERY OF CANCER GENE THERAPY

Polymorphisms in DNA Repair Gene XRCC1 and Skin Cancer Risk: A Meta-analysis

Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma

Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone

A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates

Molecular targets in the inhibition of angiogenesis

Carbonic Anhydrase IX Expression Is Associated with Improved Outcome of High-dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma

Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR)

Suchergebnisse filtern